Biogen Inc. (NASDAQ: BIIB) Stock Competitors & Peer Comparison
See BIIB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIIB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIIB | $226.67 | -0.41% | 33.8B | 14.44 | $15.84 | N/A |
| LLY | $1,177.53 | -0.50% | 1.1T | 37.65 | $31.49 | +0.56% |
| JNJ | $266.90 | -1.59% | 655.6B | 25.35 | $10.73 | +1.94% |
| ABBV | $264.01 | -0.12% | 470.7B | 26.14 | $10.19 | +2.56% |
| MRK | $147.68 | -0.74% | 367.3B | 46.32 | $3.21 | +2.29% |
| NVS | $144.93 | -0.37% | 279.3B | 16.91 | $8.69 | +3.23% |
| AZN | $164.33 | -1.35% | 257.9B | 17.96 | $9.26 | +1.94% |
| AMGN | $417.89 | +0.79% | 225.7B | 18.69 | $22.37 | +2.38% |
| GILD | $150.94 | +0.01% | 188.7B | -390.28 | -$0.39 | +2.13% |
| NVO | $38.16 | -1.65% | 171.9B | 9.63 | $4.02 | +4.65% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
BIIB vs LLY Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while LLY trades at $1,177.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas LLY's P/E ratio is 37.65. In terms of profitability, BIIB's ROE is +0.05%, compared to LLY's ROE of +0.93%. Regarding short-term risk, BIIB is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
BIIB vs JNJ Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, JNJ has a market cap of 655.6B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while JNJ trades at $266.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas JNJ's P/E ratio is 25.35. In terms of profitability, BIIB's ROE is +0.05%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, BIIB is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
BIIB vs ABBV Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, ABBV has a market cap of 470.7B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while ABBV trades at $264.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas ABBV's P/E ratio is 26.14. In terms of profitability, BIIB's ROE is +0.05%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, BIIB is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
BIIB vs MRK Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, MRK has a market cap of 367.3B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while MRK trades at $147.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas MRK's P/E ratio is 46.32. In terms of profitability, BIIB's ROE is +0.05%, compared to MRK's ROE of +0.07%. Regarding short-term risk, BIIB is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check MRK's competition here
Novartis AG (NYSE: NVS)
BIIB vs NVS Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, NVS has a market cap of 279.3B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while NVS trades at $144.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas NVS's P/E ratio is 16.91. In terms of profitability, BIIB's ROE is +0.05%, compared to NVS's ROE of +0.30%. Regarding short-term risk, BIIB is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
BIIB vs AZN Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, AZN has a market cap of 257.9B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while AZN trades at $164.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas AZN's P/E ratio is 17.96. In terms of profitability, BIIB's ROE is +0.05%, compared to AZN's ROE of +0.22%. Regarding short-term risk, BIIB is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
BIIB vs AMGN Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, AMGN has a market cap of 225.7B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while AMGN trades at $417.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas AMGN's P/E ratio is 18.69. In terms of profitability, BIIB's ROE is +0.05%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, BIIB is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
BIIB vs GILD Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, GILD has a market cap of 188.7B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while GILD trades at $150.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas GILD's P/E ratio is -390.28. In terms of profitability, BIIB's ROE is +0.05%, compared to GILD's ROE of -0.16%. Regarding short-term risk, BIIB is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
BIIB vs NVO Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, NVO has a market cap of 171.9B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while NVO trades at $38.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas NVO's P/E ratio is 9.63. In terms of profitability, BIIB's ROE is +0.05%, compared to NVO's ROE of +0.59%. Regarding short-term risk, BIIB is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
BIIB vs PFE Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, PFE has a market cap of 163.7B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while PFE trades at $28.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas PFE's P/E ratio is 9.42. In terms of profitability, BIIB's ROE is +0.05%, compared to PFE's ROE of +0.05%. Regarding short-term risk, BIIB is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
BIIB vs BMY Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, BMY has a market cap of 130.5B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while BMY trades at $63.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas BMY's P/E ratio is 10.77. In terms of profitability, BIIB's ROE is +0.05%, compared to BMY's ROE of +0.47%. Regarding short-term risk, BIIB is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check BMY's competition here
GSK plc (NYSE: GSK)
BIIB vs GSK Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, GSK has a market cap of 99.6B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while GSK trades at $49.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas GSK's P/E ratio is 10.73. In terms of profitability, BIIB's ROE is +0.05%, compared to GSK's ROE of +0.24%. Regarding short-term risk, BIIB is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check GSK's competition here
Sanofi (NASDAQ: SNY)
BIIB vs SNY Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, SNY has a market cap of 98.9B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while SNY trades at $40.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas SNY's P/E ratio is 8.97. In terms of profitability, BIIB's ROE is +0.05%, compared to SNY's ROE of +0.06%. Regarding short-term risk, BIIB is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check SNY's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
BIIB vs HZNP Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas HZNP's P/E ratio is 61.86. In terms of profitability, BIIB's ROE is +0.05%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, BIIB is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
BIIB vs GRFS Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, GRFS has a market cap of 6.3B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while GRFS trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas GRFS's P/E ratio is 8.51. In terms of profitability, BIIB's ROE is +0.05%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, BIIB is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
BIIB vs OGN Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while OGN trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas OGN's P/E ratio is 4.10. In terms of profitability, BIIB's ROE is +0.05%, compared to OGN's ROE of +0.23%. Regarding short-term risk, BIIB is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for BIIB.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
BIIB vs AMRN Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, AMRN has a market cap of 274M. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while AMRN trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas AMRN's P/E ratio is -132.50. In terms of profitability, BIIB's ROE is +0.05%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, BIIB is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
BIIB vs MIRA Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, MIRA has a market cap of 38M. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while MIRA trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas MIRA's P/E ratio is -0.62. In terms of profitability, BIIB's ROE is +0.05%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, BIIB is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
BIIB vs SCLX Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, SCLX has a market cap of 38M. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while SCLX trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas SCLX's P/E ratio is -0.11. In terms of profitability, BIIB's ROE is +0.05%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, BIIB is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
BIIB vs SCLXW Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, SCLXW has a market cap of 24.6M. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while SCLXW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas SCLXW's P/E ratio is N/A. In terms of profitability, BIIB's ROE is +0.05%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, BIIB is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check SCLXW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
BIIB vs CRXT Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas CRXT's P/E ratio is -0.02. In terms of profitability, BIIB's ROE is +0.05%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, BIIB is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check CRXT's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
BIIB vs BDSIW Comparison September 2026
Biogen Inc. (NASDAQ: BIIB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIIB stands at 33.8B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, BIIB is priced at $226.67 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIIB currently has a P/E ratio of 14.44, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, BIIB's ROE is +0.05%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, BIIB is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for BIIB.Check BDSIW's competition here